Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 17 May 2019, 15:34 HKT/SGT
Share:
    

Source: Eisai
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets

TOKYO, May 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction.

"SBT Initiative" is an international joint initiative by CDP which is an international NGO operating information disclosure program related to the environment field, the UN Global Compact (UNGC), the World Wildlife Fund (WWF), and the World Resources Institute (WRI). Paris Agreement includes to keep the global average temperature rise since pre-industrial revolution to below 2degC as a long-term common global goal for GHG reduction. According to this adaptation of Paris Agreement, SBT Initiative certifies companies with ambitious targets meeting the SBT "2degC target". "SBT Initiative" certified that the following Eisai's GHG emission reduction targets are recognized as based on scientific grounds and therefore approved.

- 30% reduction of GHG emission (Scope 1 and 2) by FY2030 from FY2016
- 30% reduction of GHG emission (emission based on purchased products and services in Scope 3) by FY2030 from FY2016

Scope 1: Direct emission of GHG released into the air by the use of fossil fuel
Scope 2: Indirect emission of GHG with use of electricity and steam purchased from others
Scope 3: Indirect emission of GHG by supply chain excluding Eisai

Eisai's corporate philosophy is to give first thought to patients and their families, and increase that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will strengthen the activities for climate changes and contributes to ensure the society sustainability.


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


May 17, 2019 15:34 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 18, 2020 12:33 HKT/SGT
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 14, 2020 08:22 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
Apr 27, 2020 16:26 HKT/SGT
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
Apr 1, 2020 15:23 HKT/SGT
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
Mar 26, 2020 16:01 HKT/SGT
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
Mar 25, 2020 08:38 HKT/SGT
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
Mar 23, 2020 10:53 HKT/SGT
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
Mar 19, 2020 14:15 HKT/SGT
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan
Feb 25, 2020 08:10 HKT/SGT
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Feb 21, 2020 16:55 HKT/SGT
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: